Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis

Ghaith Aljayyoussi¹, Hayley E. Tyrer¹, Louise Ford¹, Hanna Sjoberg¹, Nicolas Pionnier¹, David Waterhouse², Jill Davies³, Joanne Gamble¹, Haely Metuge²,³, Darren A. N. Cook¹, Andrew Steven², Raman Sharma¹, Ana F. Guimaraes¹, Rachel H. Clare¹, Andrew Cassidy¹, Kelly L. Johnston¹, Laura Myhill¹, Laura Hayward¹, Samuel Wanjii²,³, Joseph D. Turner¹, Mark J. Taylor¹ & Stephen A. Ward¹

Lymphatic filariasis (LF) and onchocerciasis are priority neglected tropical diseases targeted for elimination. The only safe drug treatment with substantial curative activity against the filarial nematodes responsible for LF (Brugia malayi, Wuchereria bancrofti) or onchocerciasis (Onchocerca volvulus) is doxycycline. The target of doxycycline is the essential endosymbiont, Wolbachia. Four to six weeks doxycycline therapy achieves >90% depletion of Wolbachia in worm tissues leading to blockade of embryogenesis, adult sterility and premature death 18–24 months post-treatment. Long treatment length and contraindications in children and pregnancy are obstacles to implementing doxycycline as a public health strategy. Here we determine, via preclinical infection models of Brugia malayi or Onchocerca ochengi that elevated exposures of orally-administered rifampicin can lead to Wolbachia depletions from filariae more rapidly than those achieved by doxycycline. Dose escalation of rifampicin achieves >90% Wolbachia depletion in time periods of 7 days in B. malayi and 14 days in O. ochengi.

Using pharmacokinetic-pharmacodynamic modelling and mouse-human bridging analysis, we conclude that clinically relevant dose elevations of rifampicin, which have recently been determined as safe in humans, could be administered as short courses to filariasis target populations with potential to reduce anti-Wolbachia curative therapy times to between one and two weeks.

Lymphatic Filariasis (LF) and onchocerciasis are vector-borne diseases that endure as public health problems despite the efforts of sustained elimination programmes¹–³. LF remains wide-spread throughout the tropics, affecting 120 million individuals with 1.1 billion at risk of infection⁴. It is symptomatically characterised by lymphoedema, hydrocele and elephantiasis and is the second leading cause of global disability⁵. Onchocerciasis is endemic in much of Sub-Saharan Africa, as well as more limited foci in Brazil, Venezuela and The Yemen with 37 million infected⁶⁷. Onchocerciasis is the cause of skin disease and, in its most severe presentation, a sclerosing ocular keratitis (river blindness) which affects 0.8 million individuals and is the second most prevalent cause of infection-related preventable blindness⁷–⁹. LF and onchocerciasis are both targeted for elimination as public health problems⁹¹⁰¹¹. The current strategy of elimination is mass drug administration (MDA) with anti-filarial drugs, which target the transmissive

¹Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.
²Research Foundation in Tropical Medicine and the Environment, Buea, Cameroon.
³Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon. Correspondence and requests for materials should be addressed to M.J.T. (email: Mark.Taylor@lstm.ac.uk)
first-stage larvae (microfilariae; mf) produced by mating adult filariae. For LF, the standard treatment is once single annual treatment with diethylcarbamazine (DEC) and albendazole (ABZ) in Asia, South America and Polynesia. Due to contraindications of DEC in areas of potential overlapping onchocerciasis distribution in Africa, ABZ is contraindicated (due to risk of severe ocular adverse reactions) and ivermectin (IVM) is substituted in combination with ABZ. IVM is also used as a monotherapy in once- or twice-annual MDA for the elimination of onchocerciasis. Because standard anti-filarial drugs given in these dosages and/or combinations have little macrofilaricidal activity, they have to be administered with high population coverage and repetitively over many years in order to break the transmission cycle of the long-lived, reproductively active adult filarial infections. This is predicted as at least five annual rounds for LF and fifteen annual rounds for onchocerciasis, with the former a minimum timeframe to initiate transmission assessment surveys.

MDA has undoubtedly both reduced the burden of onchocerciasis disease and achieved nationwide elimination outcomes for LF in certain country settings. In other countries, however, failures of the approach are manifest. ‘Hot-spot’ residual foci of infections persist despite sustained coverage due to emerging resistance or other factors, in certain regions, poor adherence to treatment is recorded, in part due to incidence of severe neurological adverse reactions to Loa loa co-infections in hard-to-reach areas, inadequate coverage is apparent and certain country elimination programmes are yet to commence. In these scenarios, if LF and onchocerciasis elimination targets within ambitious United Nations Sustainable Development Goal (SDG) timeframes are to be achieved, there is an urgent need to implement alternative strategies. Affordable registered drugs, which have evidence of curative activity against filariae, and could be re-purposed to cure target populations within a test-and-treat delivery, are considered the most expeditious solution toward achieving elimination targets where deployed to mop up residual foci during the elimination ‘end-game’.

The antibiotic, doxycycline, has been shown to indirectly exert significant macrofilaricidal activity by targeting the filarial endosymbiotic bacteria (Wolbachia). Through a series of clinical trials in LF and onchocerciasis patients, sustained, >90% depletion of Wolbachia from filarial tissues consequently mediates inhibition of embryogenesis, infertility, clearance of mf from the blood or skin and ultimately death of the adult filariae in 18–24 months. Effects of depleting Wolbachia within migratory mf have also been demonstrated to hinder development to the infectious larval stage in intermediate vectors. Sustained amicrofilaraemia following a single course of doxycycline leads to symptomatic relief and halts disease progression in onchocerciasis and interrupts transmission in both LF and onchocerciasis. Dose regimen reductions during clinical studies and subsequent modelling of curative trial outcomes for onchocerciasis have defined that doxycycline achieves significant macrofilaricidal activity via >90% Wolbachia depletion in both LF and onchocerciasis. After 4 to 6 weeks of daily administration, dependent on dose (100 or 200 mg) and the target organism, (Wuchereria, Brugia or Onchocerca).

However, two major impediments remain for the implementation of an anti-Wolbachia therapeutic approach based on doxycycline. The long treatment duration of 4 weeks minimum imposes a logistical challenge and risk poor adherence, whereby shorter durations of doxycycline treatment, although achieving significant Wolbachia reductions and impacting on embryogenesis, fail to achieve significant curative outcomes. Secondly, doxycycline is contraindicated in significant proportions of the population such as in pregnancy and children of 8 years of age or younger.

In this work, a strategy for achieving the equivalent efficacy of long-course doxycycline treatment by using a high dose of rifampicin for 1–2 weeks is presented. For this, preclinical in vivo mouse models of Brugia malayi or Onchocerca ochengi adult worm infections, are used to compare the activity of different orally administered dosages to establish a PK-PD relationship of rifampicin that is translatable to humans. Using these empirical rifampicin experiments and PK-PD analysis we provide preclinical evidence to justify phase II trials re-purposing high dose rifampicin to deliver curative outcomes in periods of between 1 to 2 weeks.

### Results

#### Intrinsic anti-Wolbachia potency of rifampicin is superior to doxycycline.

Table 1 shows in its first row, the in vitro IC₅₀ levels obtained for doxycycline and rifampicin in the Wolbachia infected C6/36 cell (C6/36 wAlbB) assay. Rifampicin exhibited an EC₅₀ of 1.3 nM, which was approximately 16.2-fold more potent than that of doxycycline (EC₅₀ = 22 nM), against Wolbachia. Both drugs resulted in killing ~90% of Wolbachia in comparison to vehicle control cell cultures at the end of the 7 day experiment.

#### Pharmacokinetics of rifampicin are superior to doxycycline.

Figure 1 shows the pharmacokinetic profiles measured in SCID mice at days 1 and 7 for doxycycline or rifampicin at a dose of 25 mg/kg bid. Table 2 summarises the pharmacokinetic parameters of each drug. Rifampicin (CL/F = 0.11 L/hr/kg) exhibited ~10 fold higher exposure at the same dose than doxycycline (CL/F = 1.2 L/hr/kg). Clearance values at day 1 and day 7 were not statistically different (Mann-Whitney test, n = 5 mice, P > 0.05) and as shown in Table 2 all pharmacokinetics parameters of both drugs did not significantly change after chronic exposure in comparison to single dose administration.

### Table 1. In-vitro and in-vivo IC₅₀ values of doxycycline and rifampicin calculated based on the individual potency of each drug in the dose escalation studies in animals using PK-PD modelling.

| Drug      | Doxycycline IC₅₀ (mg/mL) | Rifampicin IC₅₀ (µg/mL) | Ratio (doxycycline/rifampicin) |
|-----------|--------------------------|-------------------------|--------------------------------|
| In-vitro  | 22                       | 1.3                     | 16.9                           |
| In-vivo   | 1059                     | 65                      | 16.3                           |

Table 1. In-vitro and in-vivo IC₅₀ values of doxycycline and rifampicin calculated based on the individual potency of each drug in the dose escalation studies in animals using PK-PD modelling.
Anti-Wolbachia activity of rifampicin is superior to doxycycline in adult filarial infection models. We compared the anti-Wolbachia activity of rifampicin (5 mg/kg qd, 15 mg/kg qd, 35 mg/kg qd or 25 mg/kg bid) with doxycycline (25 mg/kg bid) in B. malayi and O. ochengi SCID mouse models (Fig. 2). The murine doxycycline dose had been previously defined as bioequivalent to clinical dosing with 100 mg/day. Wolbachia rate-of-kill was examined by four day dosing of mice infected with adult-stage B. malayi followed by termination +24 h after last dose and retrieval of female adults for assessment of Wolbachia loads (Fig. 2a). Changes in Wolbachia post-dosing were calculated as a % reduction compared with the median level in the vehicle control group. Bioequivalent doxycycline mediated a 41.3% reduction in Wolbachia after +4 day exposures. In comparison, low dose rifampicin (5 mg/kg qd) mediated a significantly higher 66.3% reduction over the same time period (1 way ANOVA F = 7.561, P = 0.002, Dunnett’s multiple comparisons test P < 0.05 vs DOX; Fig. 2b) whilst high dose rifampicin (15 mg/kg qd) mediated a 76.0% median reduction (P < 0.01 vs DOX; Fig. 2b).

Elevations in oral rifampicin dose were undertaken to evaluate whether >90% threshold level Wolbachia depletions in female filarial tissues could be achieved in a time frame of seven days dosing. Six to seven week-old B. malayi timed infections were targeted with an additional washout period of five weeks to allow for continued
depletion or recrudescence of the Wolbachia population to be evident, as previously reported\textsuperscript{59,60} (Fig. 2c). Doxycycline, at human bioequivalent (100 mg/day) dose\textsuperscript{58}, was administered for four or six weeks (the latter a clinical dose time frame proven to deliver >90% Wolbachia depletion in \textit{B. malayi}\textsuperscript{39} to compare with the efficacy

---

**Figure 2.** Pharmacological Outputs: Anti-filarial, anti-\textit{Wolbachia} pharmacological effects of doxycycline (DOX) and rifampicin (RIF) \textit{in vivo}. Immediate pharmacological effects of DOX and RIF on \textit{Brugia malayi} female adult Wolbachia loads (\textit{a,b}) or post-washout (\textit{c,d}). Effects on \textit{B. malayi} microfilariae (\textit{Bm}\textit{mf}) production (\textit{e}). Effects on \textit{Onchocerca ochengi} male adult Wolbachia loads post-washout (\textit{f,g}). Box and whiskers represent min-max (n = 10–29; \textit{B. malayi} Wolbachia, n = 4–25; \textit{Bm}\textit{mf}, n = 5–17 \textit{O. ochengi} Wolbachia). Solid line = control median Wolbachia level, long dashed line = 90%, short dashed line = 99% depletion level. Significance indicated *\textit{P*} < 0.05, **\textit{P*} < 0.01, ***\textit{P*} < 0.001, ****\textit{P*} < 0.0001.

---

doxycycline, at human bioequivalent (100 mg/day) dose\textsuperscript{58}, was administered for four or six weeks (the latter a clinical dose time frame proven to deliver >90% Wolbachia depletion in \textit{B. malayi}\textsuperscript{39} to compare with the efficacy
of increasing dosages of short-course rifampicin regimens. As expected for ‘slow-killing’ anti-\textit{Wolbachia} macrofilaricides, there were no significant changes in \textit{B. malayi} worm burdens in either doxycycline or rifampicin dosed mouse groups compared with vehicle controls (Table 3). Doxycycline mediated an 88.1% median reduction in \textit{Wolbachia} after four week dosing and 99.76% median reduction after six week dosing. In comparison, low dose rifampicin (5 mg/kg \textit{qd} x 7d) was sub-optimal and statistically inferior to doxycycline, with a 58.3% median reduction (Kruskal-Wallis test $P < 0.0001$, Dunn’s multiple comparisons test, $P < 0.0001$ vs +42d DOX; Fig. 2d). Elevation of rifampicin dose to 15 mg/kg \textit{qd}, 35 mg/kg \textit{qd} or 25 mg/kg \textit{bid} delivered 97.7%, 98.2% or 99.5% median \textit{Wolbachia} reductions, respectively. These dose effects were statistically non-inferior to six-week doxycycline dosing. Rifampicin 25 mg/kg \textit{bid} dosing for seven days displayed significantly superior anti-\textit{Wolbachia} activity to four-week doxycycline ($P < 0.0001$) and 15 mg/kg \textit{qd} or 25 mg/kg \textit{bid} rifampicin were superior to 5 mg/kg rifampicin after seven day dosing ($P < 0.05$ and $P < 0.0001$, respectively; Fig. 2d). Examining the impact of anti-\textit{Wolbachia} efficacy on mf release, four or six-week doxycycline mediated a complete absence of viable mf within the peritoneal infection site (5/5 or 4/4 mice mf negative vs 2/25 mf negative; Fig. 2e). Seven-day doses of rifampicin exceeding 15 mg/kg \textit{qd} mediated a near complete absence of viable mf from the peritoneum of infected mice (11/12 mice mf negative; Fig. 2e). Seven-day doses of rifampicin exceeding 15 mg/kg \textit{qd} mediated total absence of viable mf (35 mg/kg \textit{qd}; 4/4 mice mf negative $P < 0.05$ vs vehicle, 25 mg/kg \textit{bid}; 9/9 mice mf negative $P < 0.001$ vs vehicle; Fig. 2e). Based on threshold effects of elevated dose rifampicin achieving $>90\%$ \textit{Wolbachia} depletions from \textit{Brugia} adult female tissues following seven day dosing, we tested efficacy against \textit{Onchocerca} male worms in a novel SCID mouse model of onchocerciasis\textsuperscript{25}. Rifampicin dosed at 35 mg/kg \textit{qd} for seven or 14 days was compared with human bioequivalent doxycycline dosed for 28 days (a minimum clinical dose/duration determined to deplete $>90\%$ \textit{Wolbachia} from adult \textit{O. volvulus} tissues leading to macrofilarial activity\textsuperscript{40}) (Fig. 2f). Male \textit{Onchocerca} worm burdens were not affected by treatment compared with vehicle controls (Table 3). Bioequivalent doxycycline mediated 99.6% median reduction in \textit{Wolbachia} from male \textit{Onchocerca} tissues following 28 days dosing (Fig. 2g). Seven-day dosing of rifampicin did not mediate any depletion in \textit{Wolbachia} following washout period (0% median reduction) and was thus statistically inferior to doxycycline control (Kruskal-Wallis test $P = 0.0013$, Dunn’s multiple comparisons test, $P < 0.001$ vs DOX; Fig. 2g). In comparison, 14 day dosing of rifampicin mediated 96.9% median reductions in \textit{Onchocerca Wolbachia}, a level of efficacy that was statistically non-inferior to doxycycline dosed for 28 days (Fig. 2g).

### PK-PD modelling.

The empirical PK and pharmacological anti-\textit{Wolbachia} efficacy measurements of doxycycline and rifampicin were used to construct a PK-PD model (described in the methods section). An \textit{in vivo} IC\textsubscript{50} value was calculated based on the model for rifampicin (65.2 µg/ml), which was $16$-fold more potent than that calculated for doxycycline (1059 µg/ml; Table 1). IC\textsubscript{50} values derived from the PK-PD model were 100,000 to 200,000 fold higher than those observed \textit{in vitro}; however the ratio of calculated \textit{in vivo} IC\textsubscript{50} between rifampicin and doxycycline was aligned to the ratio empirically measured \textit{in vitro} between the two drugs ($17$-fold higher RIF vs DOX, Table 1).

### Mouse – Human Bridging analysis.

To compare rifampicin exposures observed in the SCID mouse model in comparison to those achieved in standard human clinical dose (600 mg), the overall exposure of rifampicin has been estimated in humans based on literature data (Fig. 3a). From this we determined the exposure in an average population of 70 kg humans after receiving 600 mg dose of rifampicin is significantly lower than the

| Treatment Species | Vehicle \textit{B. malayi} | DOX \textit{B. malayi} | RIF \textit{B. malayi} | Vehicle \textit{O. ochengi} | DOX \textit{O. ochengi} | RIF \textit{O. ochengi} |
|-------------------|--------------------------|------------------|------------------|--------------------------|------------------|------------------|
| **Dose (mg/kg)**  | —                        | 25               | 25               | —                        | 25               | 25               |
| **Doses/day**     | —                        | bid              | bid              | qd                       | qd               | qd               |
| **Duration (d)**  | 28–42                    | 28               | 42               | 7                        | 7                | 7                |
| **SCID mouse (n)**| 25                       | 5                | 4                | 12                       | 4                | 9                |
| **Total worm (n)**| 248                      | 27               | 67               | 73                       | 34               | 78               |
| **Min**           | 0                        | 0                | 14               | 0                        | 0                | 15               |
| **Median**        | 9                        | 6                | 24               | 23                       | 8                | 20               |
| **Max**           | 34                       | 10               | 29               | 27                       | 9                | 23               |
| **Female \textit{B. malayi} (n)** | 159                  | 17               | 49               | 54                       | 22               | 51               |
| **Min**           | 0                        | 0                | 11               | 0                        | 0                | 0                |
| **Median**        | 6                        | 4                | 15               | 12.5                     | 1                | 16.5             |
| **Max**           | 23                       | 7                | 23               | 18                       | 6                | 18               |
| **Wolbachia sample (n)** | 53                        | 15               | 10               | 10                       | 21               | 10               |

**Table 3.** Adult \textit{B. malayi} or \textit{O. ochengi} worm burden recoveries post-dosing.
optimal exposure in mice that results in >90% *Wolbachia* elimination in 7 days or less (this exposure is defined as the 24 hour steady state AUC of the 15 mg/kg rifampicin dose in mice which is 141.5 mg/hr/L). The human dose that would achieve this optimal mouse exposure was then determined via multiple Monte-Carlo simulations (3000 subjects per dose) at different doses from 5 mg/kg up to 45 mg/kg where the percentage of humans predicted to achieve the desired AUC at each dose has been recorded (Fig. 3b). The PK predictions of higher doses of Rifampicin agree with published results where the predicted C\text{max} and AUC were equivalent to observed PK in humans at elevated doses in clinical studies\textsuperscript{61}. This would indicate that our dosing suggestion will achieve the desired exposure based on clinical PK data.

From those simulations, it is predicted that a minimum dose of 30–40 mg/kg is needed to achieve ‘curative’ exposure levels in human filariasis patients which also agrees with high dose RIF clinical studies\textsuperscript{61} that have shown a dose of 30 mg/kg or higher to achieve a steady-state AUC of 141.5 mg/hr/L in the vast majority of patients

**Discussion**

Targeting *Wolbachia* with antibiotics to deliver curative outcomes for filariasis is a promising drug development strategy. The pharmacopeia of registered antibiotics present ‘low hanging fruit’ with the potential for rapid re-purposing\textsuperscript{62,63}. Further, the ‘slow kill’ effect post-*Wolbachia* depletion, manifest first on circulating or skin mf and then adult worms, avoids the problems of inflammatory adverse reactions which are associated with fast-killing direct filaricidal agents\textsuperscript{3,33,64–66}. Indeed, this promotes anti-*Wolbachia* therapies as a safe drug development strategy for to administer to *L. loa* co-endemic target populations\textsuperscript{67} who are at risk of severe neurological adverse reactions to rapid acting filaricides and thus provides a potential solution to problem areas of Central Africa toward an end game of onchocerciasis elimination\textsuperscript{68}. Clinical trials with doxycycline have shown that
depletion of *Wolbachia* from filarial nematodes can deliver significant macrofilaricidal activity when administered for 4 or more weeks\(^{38,40-42,51}\). However, the long period of administration and contraindications in children and pregnant women present logistical challenges to widespread scale-up in resource poor settings of Sub-Saharan Africa. Whilst we have recently identified minocycline as a superior anti-*Wolbachia* agent to doxycycline in the *B. malayi* SCID mouse model\(^{38}\) as part of the same tetracycline class, the same contraindications would apply. The ‘holy grail’ for an anti-*Wolbachia* macrofilaricide is thus demonstrable activity in administration times of a minimum of 2 weeks (ideally 1 week) and a safety profile for administration in loiasis co-infections, in children and in pregnant women\(^{34,63}\).

We use here a validated screening system of *in vitro* cell assays and *in vivo* preclinical mouse models of filariasis\(^{56,57}\) to test the efficacy of dose elevations of rifampicin and have identified a dose-dependent activity which has the potential to achieve *Wolbachia* depletions predictive of cure when administered for 1 week against the human lymphatic filaria *B. malayi* or 2 weeks against *O. ochengi*, the closest phylogenetic relative of *O. volvulus*.

We determine that rifampicin is >15 fold more potent than doxycycline in *vitro*. Rifampicin exhibited significantly higher exposure per mg dose when compared to doxycycline. Also PK-PD modelling showed that rifampicin is more potent in reducing *Wolbachia* in *vitro* when exposure levels are matched to doxycycline. This superiority likely reflects the inherently higher (>16 fold) intrinsic potency of rifampicin against *Wolbachia* that is observed *in vitro* compared with doxycycline.

Corroborating rifampicin superiority versus doxycycline as an anti-*Wolbachia* agent, it has previously been reported, in mice experimentally infected with the rodent filaria, *Litomosoides sigmodonitis*, that 25 mg/kg bid dosages of rifampicin result in a more profound decrease in *Wolbachia* levels in adult worms when compared to a similar dose of doxycycline\(^{44}\). Also, in a pilot study using the related, registered rifamycin, rifampentine, >90% depletion of *Wolbachia* was measured in *O. ochengi* males implanted into SCID mice, following two weeks 25 mg/kg bid dosing\(^{56}\). However, clinical studies in humans have shown that rifampicin administered for two or four weeks has inferior activity to six-week doxycycline in onchocerciasis\(^69,70\) and neither is combining rifampicin and doxycycline for two weeks sufficient to achieve significant macrofilaricidal activity\(^{54}\).

Our PK-PD model offers a rational explanation for the discrepancy in the activity of rifampicin in mice and humans, where doxycycline activity is similar across mouse model and human clinical studies, yet rifampicin seems to be dramatically more active in the mouse than in humans. We identify effective dosages in the mouse exceed the exposure of rifampicin achieved in humans when the drug is administered at ‘standard dose’ (∼10 mg/kg qd or 600 mg). Indeed, exploring dose ranges more in line with standard human dose exposures, (5 mg/kg qd) rifampicin in the mouse is insufficient to achieve >90% *Wolbachia* depletion in 1 week against *B. malayi*.

The currently established 600 mg dose of rifampicin has not been predicated on PK-PD analysis but rather has been chosen based on drug cost, due to rifampicin semi-synthetic production in the 1970’s when the dosage was established\(^{51}\). However, recently the cost of rifampicin production has dramatically decreased and dose escalation studies have been initiated for TB patients. Higher doses of rifampicin (up to 35 mg/kg) have recently been proven to be safe in a clinical study\(^{66}\). The same study undertook human PK analysis and has shown that rifampicin exposure increases as the dose is increased. From this data we predict that the target exposure level required to deplete >90% *Wolbachia* from target filarial species in 1–2 weeks to ultimately deliver short-course curative efficacy against filariasis is achievable in humans when a dose of 30–35 mg/kg is administered. Importantly, clinical data supports that for doses of up to 35 mg/kg, given for periods over 2 weeks, no serious side effects are observed and that grade 1 and grade 2 side effects are randomly distributed across low and higher doses indicating no increased risk of side effects with elevated doses of rifampicin. A recent additional study where a dose of 35 mg/kg of RIF was administered to TB patients has also reported similar conclusions in relation to safety\(^{73}\).

Because elevated rifampicin dosages for filariasis cure are predicted in a 1–2 week dose exposure time frame, this is unlikely to result in resistant strains of *M tuberculosis* (TB), as there is no evidence for rifampicin resistance occurrence when administered for short periods of time\(^{73,74}\).

Rifampicin has a number of drug-drug interactions of clinical significance that have been previously reported\(^{35}\). Those interactions can result in the reduction of exposure of other drugs that are taken concomitantly with Rifampicin, and doses might need to be altered, especially for patients who are on HIV medication.

**Conclusions**

Using PK-PD modelling of drug activity in preclinical filarial mouse models, we show that a clinically safe dose of rifampicin can be administered for 1–2 week short courses to elicit >90% reductions in *Wolbachia*, predictive of the macrofilaricidal activity observed when *Wolbachia* is targeted by doxycycline, administered for 4–6 weeks. This treatment regimen would be compatible for use in children and during pregnancy and, because of the shortened duration of administration required, would be more readily deliverable by health care systems in resource-poor community settings. A 35 mg/kg dose has been proven as safe over a period of 2 weeks, and it has previously been shown that such short durations of treatment will not produce resistant strains of *M. tuberculosis*. We recommend that both a 35 mg/kg 1 and 2 week dose of rifampicin be urgently examined in lymphatic filariasis and onchocerciasis randomised controlled clinical trials to test whether such short-course treatment regimens are indeed sufficient to elicit equivalent curative activities to long course doxycycline.

**Methods**

**Mice.** Six to ten week old male BALB/c SCID (Harlan Laboratories, UK) or male CB.17 BALB/c SCID mice (Charles River, UK) were used for experiments. Mice were kept at the Biomedical Services Unit (BSU) at the University of Liverpool, UK, in specific pathogen-free (SPF) conditions or at The Research Foundation for Tropical Medicine and The Environment, Buea, Cameroon, in individually-ventilated caging. All experiments on animals were approved by The Animal Welfare and Ethical Review Board, Liverpool School of Tropical Medicine,
UK, or the University of Buea Animal Ethics Review Board, Cameroon. Studies were conducted in accordance with Home Office legislation (UK) and matching welfare standards were applied in Cameroon.

**In vitro potency studies.** The anti-Wolbachia potency of doxycycline and rifampicin for use in the PK-PD model was determined in vitro, utilising the routine A-WOL screening assay as described previously. In brief the mosquito (Aedes albopictus) derived cell line C6/36 (ATCC number CRL-1660), stably infected with Wolbachia pipiensis (wAlbB) (C6/36 wAlbB) was incubated with the relevant drugs in a concentration range in order to determine a dose response. The drugs were incubated for 7 days with 2,000 cells per well on a 384 well plate (CellCarrier-384 Ultra, PerkinElmer) in Leibovitz media (Life Technologies) supplemented with 20% foetal bovine serum (FBS, Fisher Scientific), 2% tryptose phosphate broth (Sigma-Aldrich) and 1% non-essential amino acids (Sigma-Aldrich). The end-point read out utilised DNA staining of both the host cell nuclei and intracellular Wolbachia (SYTO® 11) combined with a high content imaging system (Operetta®, PerkinElmer) and analysed using the associated Harmony® software through a cytoplasm texture analysis.

**Brugia malayi experimental infections.** The Brugia malayi lifecycle was maintained through mosquitoes and susceptible Meriones gerbils at LSTM. To generate infective *B. malayi* larvae for infections, female adult *Aedes aegypti* mosquitoes were fed with microfilariae collected from infected gerbils by catheterisation, as described previously, that were mixed with human blood. Mosquitoes were fed through an artificial membrane feeder (Hemotek®). Blood-fed mosquitoes were reared for 14 days to allow for development to the L3 stage. L3 were then collected from infected mosquitoes by crushing and concentrated using a Baermann’s apparatus and RPMI medium. 100 motile L3 were collected and then injected into mice via the intra-peritoneal route. Efficiency of inoculations was confirmed by needle washout.

**Onchocerca ochengi surgical implantations.** Viable male *Onchocerca ochengi* were aseptically isolated from naturally parasitized cattle as described previously. Between 10–11 male *Onchocerca* were surgically implanted into the peritoneal cavity of CB.17(BALB/c) SCID mice under anaesthesia as described previously.

**Drug treatments.** Six weeks after *B. malayi* experimental infection or 3 days post *O. ochengi* surgical implantation, SCID mice received 100μL compound via oral gavage at variable doses and for variable treatment lengths as described and indicated in further detail in the main text. The drug doses and routes used were: Doxycycline (25 mg/kg qd or bid po) and rifampicin (1.25 mg/kg–25 mg/kg qd or bid po). Doxycycline was dissolved in water, while rifampicin was dissolved in 55% polyethylene glycol 300; 25% propylene glycol; 20% water. All drugs and vehicle reagents were purchased from Sigma Aldrich.

**Parasitological readouts.** Seven or twelve weeks after *B. malayi* experimental infection or 38 days after *O. ochengi* surgical implantation, mice were necropsied. Adult filariae and released *B. malayi* mf were recovered by a combination of peritoneal washings using wash media (RPMI containing P/S) and subsequent dissection of abdominal cavities. To quantify *B. malayi* mf, samples were centrifuged at 1200 rpm for 5 min. Excess supernatants were removed and the remaining volume quantified. Three 20μL volumes were then enumerated for mf by microscopy, scoring as motile or stretched immotile. Adult filariae were observed for motility, washed in cold PBS and parasite stages enumerated. A minimum of ten *B. malayi* females and five *O. ochengi* males per treatment group of 3–5 mice were collected into individual Eppendorf tubes to be processed for qPCR.

**DNA extraction and PCR quantification of Wolbachia.** DNA was extracted from worm samples using a DNA Blood and Tissue Kit (Qiagen) according to manufacturer’s instructions. Levels of *Bm Wolbachia* surface protein (*wsp*) gene copy numbers were quantified using qPCR as previously described. Levels of *Onchocerca Wolbachia wsp* and filarial *ggt* gene copy numbers were similarly quantified as previously described.

**PK Studies.** To establish the pharmacokinetic profiles of rifampicin and doxycycline, rich pharmacokinetic studies were performed in uninfected male SCID mice (weight 24–28 g). Doxycycline (25 mg/kg bid) or rifampicin (5 mg/kg qd or 25 mg/kg bid) were administered orally for up to seven days. For all PK studies, a total of 11 samples were collected at discrete time points between 0 and 24 hour post dose at days 1 and 7. Serial blood samples were collected at days 1 and 7 of dosing on a 384 well plate (CellCarrier-384 Ultra, PerkinElmer) in Leibovitz media (Life Technologies) supplemented with 20% foetal bovine serum (FBS, Fisher Scientific), 2% tryptose phosphate broth (Sigma-Aldrich) and 1% non-essential amino acids (Sigma-Aldrich). The end-point read out utilised DNA staining of both the host cell nuclei and intracellular Wolbachia (SYTO® 11) combined with a high content imaging system (Operetta®, PerkinElmer) and analysed using the associated Harmony® software through a cytoplasm texture analysis.

**Bioanalysis.** Rifampicin concentrations were determined by LCMS (liquid chromatography mass spectrometry) using an appropriate internal standard and were validated to internationally recognised acceptance criteria [FDA-guidelines]. Chromatographic separation was achieved using a gradient programme. The UHPLC (ultra-high pressure liquid chromatography) system was interfaced with a triple-quadrupole TSQ Quantum Access mass spectrometer (Thermo Scientific, Hemel Hempstead, UK) with a heated-electrospray ionization (H-ESI) source. An E2M28 rotary vacuum pump (Edwards High Vacuum International, West Sussex, UK), an NM30LA nitrogen generator (Peak Scientific, Renfrewshire, UK) and 99% pure argon gas (10 L, BIP10, Air Products, Liverpool, UK) were used. Blood samples (20μL) containing rifampicin were extracted with a mixture of acetonitrile and methanol (80:20 v/v). The subsequent mix was then filtered through 96 well filter plate (Millipore, UK). The resultant filtrate was then transferred to a 96 deep well plate containing 40μL of (10 mg/ml) ascorbic acid, 10μL of this resultant mixture was then injected into the LC-MS/MS. The assay was linear in the range 10–10,000 ng/ml for rifampicin.

**PK-PD Modelling.** A PK-PD model as described in equations 1 and 2 has been developed and used to fit parasitological read-outs from experiments in infected mice. The pharmacological output for all PK/PD analyses
was Wolbachia counts as estimated in qPCR experiments in the quantitation of wsp DNA levels. Pmetrics® was used in modelling PK/PD data in all experiments. The following differential equations were used:

For the PK component:

$$C_p = \frac{F \cdot \text{DOSE} \cdot k_a}{V \cdot (k_d - k_a)} \cdot [e^{-k_d \cdot t} - e^{-k_a \cdot t}]$$

Where $C_p$ is the drug concentration in blood at any given time, $F$ is the fraction available for oral absorption, $k_a$ is the rate of absorption from gut to blood, $V$ is the volume of distribution and $k_d$ is the rate of elimination from the systemic circulation.

For the PD component, a relationship was built to describe the effect of the drug upon Wolbachia levels using a dynamic $E_{max}$ model:

$$\text{Wolbachia count} (X_1) = X_1 \cdot \frac{k_{growth} - k_{kill} \cdot C_p}{IC_{50} \cdot C_p}$$

$X_1$ is the observed Wolbachia levels as estimated by qPCR, $k_{growth}$ is the rate of bacterial growth which was set at 0 due to the absence of any evidence of bacterial growth beyond the time of treatment and no evidence of recrudescence within the time frame of the experiment. $k_{kill}$ is the maximum possible rate of kill of bacteria and has been fixed to the in vitro kill rate that could be achieved at the maximum concentration of drug. $IC_{50}$ is the blood concentration required to achieve 50% of the maximal kill rate of Wolbachia in the adult worm in the mouse.

**Statistics.** PK parameters between doxycycline and rifampicin were compared by Mann-Whitney test. Percentage Wolbachia reductions in filariae following in vivo treatments were calculated from median vehicle control levels derived from the same experimental infection and screen. Where repeat experiment data (Wolbachia loads normalised to control, worm enumerations or viable mf enumerations per mouse) were available, data was pooled. Grouped continuous variables were tested for normal distribution by D’Agostino & Pearson omnibus normality tests. Continuous variables failing normal distribution tests were Log^10 transformed and re-tested. Continuous variables satisfying the assumptions of normal distribution were examined by 1-way ANOVA with Dunnett’s multiple tests post-hoc. Variables not satisfying the assumption of normality were compared by Kruskal-Wallis Test with Dunn’s Multiple Tests, post-hoc. Significance levels are indicated $P < 0.05$, $P < 0.01$ **$P < 0.001$*** $P < 0.0001$****. All statistics were undertaken using GraphPad Prism v6 software.

**References**

1. WHO. Meeting of the International Task Force for Disease Eradication, January 2014. Relevé epidemiologique hebdomadaire/Section d’hygiène du Secretariat de la Societe des Nations = Weekly epidemiological record/Section of the Secretariat of the League of Nations 89, 153–160 (2014).

2. Bockarie, M. J., Kelly-Hope, L. A., Rebollo, M. & Molyneux, D. H. Preventive chemotherapy as a strategy for elimination of neglected tropical parasitic diseases: endgame challenges. Philosophical Transactions of the Royal Society of London B: Biological Sciences 368, 20120144 (2013).

3. Taylor, M. J., Hoerauf, A. & Bockarie, M. Lymphatic filariasis and onchocerciasis. Expert opinion on pharmacotherapy 23, 5150–5157 (2012).

4. Molyneux, D. H. & Zagaria, N. Lymphatic filariasis elimination: progress in global programme development. Expert review of anti-infective therapy 10, 163–176 (2014).

5. Ottesen, E., Duke, B., Karam, M. & Behbehani, K. Strategies and tools for the control/elimination of lymphatic filariasis. Philosophical Transactions of the Royal Society of London B: Biological Sciences 368, 20121409 (2013).

6. WHO. Onchocerciasis Factsheet No 374 (2016).

7. WHO. Onchocerciasis and its control: Report of a WHO Expert Committee on Onchocerciasis Control (1995).

8. WHO. Meeting of the International Task Force for Disease Eradication, January 2014.
58. Sharma, R. et al. Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis. Scientific reports 6 (2016).
59. Gilbert, J. et al. Antibiotic chemotherapy of onchocerciasis: in a bovine model, killing of adult parasites requires a sustained depletion of endosymbiotic bacteria (Wolbachia species). Journal of Infectious Diseases 192, 1483–1493 (2005).
60. Makepeace, B. L., Rodgers, L. & Trees, A. J. Rate of elimination of Wolbachia ppssants by doxycycline in vitro increases following drug withdrawal. Antimicrobial agents and chemotherapy 50, 922–927 (2006).
61. Boeree, M. J. et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. American journal of respiratory and critical care medicine 191, 1058–1065, https://doi.org/10.1164/rccm.201407-1264OC (2015).
62. Johnston, K. L., Ford, L. & Taylor, M. J. Overcoming the challenges of drug discovery for neglected tropical diseases: the A.WOL experience. Journal of biomolecular screening 20, 335–343, https://doi.org/10.1002/jbio.201409.001 (2014).
63. Johnston, K. L. et al. Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis. International journal for parasitology. Drugs and drug resistance 4, 278–286, https://doi.org/10.1016/j.ijdrr.2014.09.001 (2014).
64. Boatin, B. A. & Richards, F. O. Control of onchocerciasis. Advances in parasitology 84, 399–396 (2006).
65. Kamgno, J., Gardon, J., Gardon-Wendel, N., Duke, B. O. & Boussinesq, M. Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly. Transactions of the Royal Society of Tropical Medicine and Hygiene 98, 496–504 (2004).
66. Hoerauf, A., Pfarr, K., Mand, S., Debrah, A. & Specht, S. Filariais in Africa—challenge and prospects. Clinical Microbiology and Infection 17, 977–985 (2011).
67. McGarry, H. F. et al. Evidence against Wolbachia symbiosis in Loa loa. Filariasis journal 2, 9, https://doi.org/10.1186/1475-2883-2-9 (2003).
68. Wanji, S. et al. Relationship between oral declaration on adherence to ivermectin treatment and parasitological indicators of onchocerciasis in an area of persistent transmission despite a decade of mass drug administration in Cameroon. Parasit Vectors 8, 667, https://doi.org/10.1186/s13071-015-1283-6 (2015).
69. Specht, S. et al. Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus. Parasitology research 103, 1303–1309, https://doi.org/10.1007/s00436-008-1133-y (2008).
70. Richards, F. O. Jr. et al. No depletion of Wolbachia from Onchocerca volvulus after a short course of rifampin and/or azithromycin. Am J Trop Med Hyg 77, 878–882 (2007).
71. van Ingen, J. et al. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? Current medical research and opinion 25, 1–12, https://doi.org/10.1185/03007995.2012.747952 (2013).
72. Boeree, M. J. et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. The Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(16)30274-2 (2016).
73. Acoolla, G., Brumfitt, W. & Hamilton-Miller, J. M. Evidence that rifampicin can be used safely for non-tuberculous diseases. Thorax 35, 788–791 (1980).
74. Gruneberg, R. N., Emmerson, A. M. & Cremer, A. W. Rifampicin for non-tuberculous infections? Chemotherapy 31, 324–328 (1985).
75. Baciewicz, A. M., Chrisman, C. R., Finch, C. K. & Self, T. H. Update on rifampin, rifabutin, and rifapentine drug interactions. Current medical research and opinion 29, 1–12, https://doi.org/10.1183/00015988.2012.1473-3099 (2013).
76. McGarry, H. F., Plant, L. D. & Taylor, M. J. Duryley/carbamazepine activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway. Filariasis journal 4, 4, https://doi.org/10.1186/1475-2883-4-4 (2005).
77. McGarry, H. F., Egerton, G. L. & Taylor, M. J. Population dynamics of Wolbachia bacterial endosymbionts in Brugia malayi. Molecular and biochemical parasitology 135, 57–67 (2004).
78. Neely, M. N., van Guilder, M. G., Yamada, W. M., Schumitzky, A. & Jelliffe, R. W. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Therapeutic drug monitoring 34, 467–476, https://doi.org/10.1097/FDM.0b013e31825c4bab (2012).

Acknowledgements
The A-WOL consortium is supported by a grant from the Bill and Melinda Gates Foundation awarded to the Liverpool School of Tropical Medicine (BMGF OPP1054324). This work was also supported by a BMGF Grand Challenges Explorations grant (OPP1119043) to JDT, SAW and MJT and a Medical Research Council New Investigator Research Grant (MR/L018756/1) to JDT.

Author Contributions
G.A., L.F., J.D.T., S.A.W. and M.J.T. wrote the paper. G.A., L.F., J.D.T., S.A.W. and M.J.T. conceived the work. G.A. and R.S. performed the PK/PD modelling analysis. H.E.T., G.A., J.G., A.G., J.D., D.W., L.F. H.S. N.P. H.M. S.W. and J.D.T. performed or directed the preclinical in vivo work (PK or PD). H.E.T., G.A., J.G., L.H., A.G., J.D., D.W., D.A.N.C. H.S. and J.D.T. performed analysis to obtain quantitative biological readouts. D.W. performed the PK bioanalysis. A.C., R.H.C., L.M., L.H., L.F. and K.L.J. performed or directed the in vitro work. A.S. and D.A.N.C. maintained the parasite lifecycle.

Additional Information

Competing Interest: The authors declare that they have no competing interests.

Change History: A correction to this article has been published and is linked from the HTML version of this paper. The error has been fixed in the paper.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. Other images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2018